started · updated
European Commission authorizes daraxonrasib for metastatic pancreatic cancer
The European Commission has authorized the sale of daraxonrasib, marketed under the name Rasonque, for the treatment of adults with metastatic pancreatic adenocarcinoma who have already received at least one systemic therapy. The decision follows an accelerated assessment by the European Medicines Agency (EMA).
Clinical data from the phase 3 RASolute 302 study indicates that the drug, which is administered as a once-daily oral tablet, significantly extends survival. Patients treated with daraxonrasib showed a median survival of approximately 12.4 to 13.2 months, compared to 6.7 months for those receiving standard chemotherapy. The treatment also doubled the median time without disease progression from 3.6 to 7.2 months.
While the authorization allows for commercialization across the European Union and the European Economic Area, individual member states must still determine pricing and reimbursement protocols. In Italy, the Italian Medicines Agency (AIFA) has initiated a rolling review to facilitate rapid access. In Spain, patient associations are calling for expedited national funding to ensure equitable access to the new therapy.
Entities
AIFA · Aiom · Castellana Grotte · European Commission · European Medicines Agency · Humanitas · IRCCS Saverio De Bellis · Italian Medicines Agency · Italy · Rasonque · Revolution Medicines · SUD4PANCREAS ODV-ETS
Claims
What the coverage asserts, and how many sources carry each claim.
- [● 15 SOURCES] The European Commission approved Rasonque (daraxonrasib) for treating adult patients with metastatic pancreatic adenocarcinoma. www.codirp.it · www.allgaeuer-zeitung.de · www.novinky.cz · www.blogsicilia.it · jurnalul.ro · +8 more
- [● 9 SOURCES] The European Medicines Agency (EMA) recommended the approval in October. www.codirp.it · www.allgaeuer-zeitung.de · jurnalul.ro · www.times.si · www.doctor33.it · +2 more
- [● 10 SOURCES] Rasonque is administered once daily as an oral tablet. www.codirp.it · www.novinky.cz · www.blogsicilia.it · www.upday.com · www.doctor33.it · +3 more
- [● 8 SOURCES] In a study of 500 patients, those receiving daraxonrasib had a median survival of 12.4 months. www.allgaeuer-zeitung.de · www.novinky.cz · jurnalul.ro · www.upday.com · www.doctor33.it · +3 more
- [● 7 SOURCES] The authorization applies to EU member states, the EEA, Iceland, Norway, and Liechtenstein. www.codirp.it · www.novinky.cz · www.greenme.it · www.blogsicilia.it · jurnalul.ro · +1 more
- [● 6 SOURCES] The drug is approved regardless of the presence of a Ras mutation in the tumor. www.codirp.it · www.doctor33.it · www.blogsicilia.it · www.periodicodaily.com · www.times.si
- [● 9 SOURCES] In the same study, patients treated with chemotherapy had a median survival of 6.7 months. www.allgaeuer-zeitung.de · www.novinky.cz · www.blogsicilia.it · jurnalul.ro · www.upday.com · +4 more
- [● 15 SOURCES] Rasonque is indicated for patients who have already received at least one systemic therapy. www.codirp.it · www.allgaeuer-zeitung.de · www.novinky.cz · www.blogsicilia.it · jurnalul.ro · +8 more
- [● 7 SOURCES] Daraxonrasib increases survival from 6.7 to 13 months in patients previously treated with chemotherapy. www.antennasud.com · www.novinky.cz · www.blogsicilia.it · jurnalul.ro · tn.nova.cz · +2 more
- [● 2 SOURCES] The clinical study was a phase 1-2 trial conducted in Spain. www.calabrianews.it · www.espressione24.it
- [○ 1 SOURCE] The drug has been approved by the U.S. Food and Drug Administration. www.antennasud.com
- [○ 1 SOURCE] There are approximately 4,000 new pancreatic cancer cases annually in Italy. www.antennasud.com